Manalo, Ceziel A.

HRN: 10-13-87  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/18/2022
CO-AMOXICLAV 625MG (TAB)
10/18/2022
10/25/2022
ORAL
625mg
Q12 X 7days
T/C Endometritis S/p Nsvd
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: